|Articles|March 28, 2019
BMS and Concerto HealthAI Agreement Accelerates Precision Oncology Innovations
Advertisement
The multi-year strategic agreement between Bristol-Myers Squibb and Concerto HealthAI announced will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials for precision treatment and improved patient outcomes.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
A Shot in the Arm to Traditional Vaccine Trial Strategy
3
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
4
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
5